Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats

J. Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A. Ehses, Nathalie Pamir, Francis C. Lynn, Shalea Piteau, Hans Ulrich Demuth, Christopher H S McIntosh, Raymond A. Pederson

Research output: Contribution to journalArticle

304 Citations (Scopus)

Abstract

Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of β-cell growth, differentiation, and cell survival to well-documented, potent insulinotropic effects. Unfortunately, the therapeutic potential of these hormones is limited by their rapid enzymatic inactivation in vivo by dipeptidyl peptidase IV (DP IV). Inhibition of DP IV, so as to enhance circulating incretin levels, has proved effective in the treatment of type 2 diabetes both in humans and in animal models, stimulating improvements in glucose tolerance, insulin sensitivity, and β-cell function. We hypothesized that enhancement of the cytoprotective and β-cell regenerative effects of GIP and GLP-1 might extend the therapeutic potential of DP IV inhibitors to include type 1 diabetes. For testing this hypothesis, male Wistar rats, exposed to a single dose of streptozotocin (STZ; 50 mg/kg), were treated twice daily with the DP IV inhibitor P32/98 for 7 weeks. Relative to STZ-injected controls, P32/98-treated animals displayed increased weight gain (230%) and nutrient intake, decreased fed blood glucose (∼26 vs. ∼20 nmol/l, respectively), and a return of plasma insulin values toward normal (0.07 vs. 0.12 mmol/l, respectively). Marked improvements in oral glucose tolerance, suggesting enhanced insulin secretory capacity, were corroborated by pancreas perfusion and insulin content measurements that revealed two- to eightfold increases in both secretory function and insulin content after 7 weeks of treatment. Immunohistochemical analyses of pancreatic sections showed marked increases in the number of small islets (+35%) and total β-cells (+120%) and in the islet β-cell fraction (12% control vs. 24% treated) in the treated animals, suggesting that DP IV inhibitor treatment enhanced islet neogenesis, β-cell survival, and insulin biosynthesis. In vitro studies using a β-(INS-1) cell line showed a dose-dependent prevention of STZ-induced apoptotic cell-death by both GIP and GLP-1, supporting a role for the incretins in eliciting the in vivo results. These novel findings provide evidence to support the potential utility of DP IV inhibitors in the treatment of type 1 and possibly late-stage type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)741-750
Number of pages10
JournalDiabetes
Volume52
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Streptozocin
Cell Survival
Incretins
Glucagon-Like Peptide 1
Insulin
Dipeptidyl Peptidase 4
Glucose
Islets of Langerhans
Type 2 Diabetes Mellitus
Peptides
Glucose Tolerance Test
Type 1 Diabetes Mellitus
Weight Gain
Insulin Resistance
Blood Glucose
Wistar Rats
Cell Differentiation
Pancreas
Reference Values

Keywords

  • DP IV, dipeptidyl peptidase IV
  • GIP, glucose-dependent insulinotropic polypeptide
  • GLP-1, glucagon-like peptide-1
  • IDGTT, intraduodenal glucose tolerance test
  • IR, immunoreactive
  • OGTT, oral glucose tolerance test
  • PDX-1, pancreatic-duodenum homeobox-1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. / Pospisilik, J. Andrew; Martin, Jennifer; Doty, Timothy; Ehses, Jan A.; Pamir, Nathalie; Lynn, Francis C.; Piteau, Shalea; Demuth, Hans Ulrich; McIntosh, Christopher H S; Pederson, Raymond A.

In: Diabetes, Vol. 52, No. 3, 01.03.2003, p. 741-750.

Research output: Contribution to journalArticle

Pospisilik, JA, Martin, J, Doty, T, Ehses, JA, Pamir, N, Lynn, FC, Piteau, S, Demuth, HU, McIntosh, CHS & Pederson, RA 2003, 'Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats', Diabetes, vol. 52, no. 3, pp. 741-750. https://doi.org/10.2337/diabetes.52.3.741
Pospisilik, J. Andrew ; Martin, Jennifer ; Doty, Timothy ; Ehses, Jan A. ; Pamir, Nathalie ; Lynn, Francis C. ; Piteau, Shalea ; Demuth, Hans Ulrich ; McIntosh, Christopher H S ; Pederson, Raymond A. / Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. In: Diabetes. 2003 ; Vol. 52, No. 3. pp. 741-750.
@article{208212fe94ef4436bc98dccbb9fb9c80,
title = "Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats",
abstract = "Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of β-cell growth, differentiation, and cell survival to well-documented, potent insulinotropic effects. Unfortunately, the therapeutic potential of these hormones is limited by their rapid enzymatic inactivation in vivo by dipeptidyl peptidase IV (DP IV). Inhibition of DP IV, so as to enhance circulating incretin levels, has proved effective in the treatment of type 2 diabetes both in humans and in animal models, stimulating improvements in glucose tolerance, insulin sensitivity, and β-cell function. We hypothesized that enhancement of the cytoprotective and β-cell regenerative effects of GIP and GLP-1 might extend the therapeutic potential of DP IV inhibitors to include type 1 diabetes. For testing this hypothesis, male Wistar rats, exposed to a single dose of streptozotocin (STZ; 50 mg/kg), were treated twice daily with the DP IV inhibitor P32/98 for 7 weeks. Relative to STZ-injected controls, P32/98-treated animals displayed increased weight gain (230{\%}) and nutrient intake, decreased fed blood glucose (∼26 vs. ∼20 nmol/l, respectively), and a return of plasma insulin values toward normal (0.07 vs. 0.12 mmol/l, respectively). Marked improvements in oral glucose tolerance, suggesting enhanced insulin secretory capacity, were corroborated by pancreas perfusion and insulin content measurements that revealed two- to eightfold increases in both secretory function and insulin content after 7 weeks of treatment. Immunohistochemical analyses of pancreatic sections showed marked increases in the number of small islets (+35{\%}) and total β-cells (+120{\%}) and in the islet β-cell fraction (12{\%} control vs. 24{\%} treated) in the treated animals, suggesting that DP IV inhibitor treatment enhanced islet neogenesis, β-cell survival, and insulin biosynthesis. In vitro studies using a β-(INS-1) cell line showed a dose-dependent prevention of STZ-induced apoptotic cell-death by both GIP and GLP-1, supporting a role for the incretins in eliciting the in vivo results. These novel findings provide evidence to support the potential utility of DP IV inhibitors in the treatment of type 1 and possibly late-stage type 2 diabetes.",
keywords = "DP IV, dipeptidyl peptidase IV, GIP, glucose-dependent insulinotropic polypeptide, GLP-1, glucagon-like peptide-1, IDGTT, intraduodenal glucose tolerance test, IR, immunoreactive, OGTT, oral glucose tolerance test, PDX-1, pancreatic-duodenum homeobox-1",
author = "Pospisilik, {J. Andrew} and Jennifer Martin and Timothy Doty and Ehses, {Jan A.} and Nathalie Pamir and Lynn, {Francis C.} and Shalea Piteau and Demuth, {Hans Ulrich} and McIntosh, {Christopher H S} and Pederson, {Raymond A.}",
year = "2003",
month = "3",
day = "1",
doi = "10.2337/diabetes.52.3.741",
language = "English (US)",
volume = "52",
pages = "741--750",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats

AU - Pospisilik, J. Andrew

AU - Martin, Jennifer

AU - Doty, Timothy

AU - Ehses, Jan A.

AU - Pamir, Nathalie

AU - Lynn, Francis C.

AU - Piteau, Shalea

AU - Demuth, Hans Ulrich

AU - McIntosh, Christopher H S

AU - Pederson, Raymond A.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of β-cell growth, differentiation, and cell survival to well-documented, potent insulinotropic effects. Unfortunately, the therapeutic potential of these hormones is limited by their rapid enzymatic inactivation in vivo by dipeptidyl peptidase IV (DP IV). Inhibition of DP IV, so as to enhance circulating incretin levels, has proved effective in the treatment of type 2 diabetes both in humans and in animal models, stimulating improvements in glucose tolerance, insulin sensitivity, and β-cell function. We hypothesized that enhancement of the cytoprotective and β-cell regenerative effects of GIP and GLP-1 might extend the therapeutic potential of DP IV inhibitors to include type 1 diabetes. For testing this hypothesis, male Wistar rats, exposed to a single dose of streptozotocin (STZ; 50 mg/kg), were treated twice daily with the DP IV inhibitor P32/98 for 7 weeks. Relative to STZ-injected controls, P32/98-treated animals displayed increased weight gain (230%) and nutrient intake, decreased fed blood glucose (∼26 vs. ∼20 nmol/l, respectively), and a return of plasma insulin values toward normal (0.07 vs. 0.12 mmol/l, respectively). Marked improvements in oral glucose tolerance, suggesting enhanced insulin secretory capacity, were corroborated by pancreas perfusion and insulin content measurements that revealed two- to eightfold increases in both secretory function and insulin content after 7 weeks of treatment. Immunohistochemical analyses of pancreatic sections showed marked increases in the number of small islets (+35%) and total β-cells (+120%) and in the islet β-cell fraction (12% control vs. 24% treated) in the treated animals, suggesting that DP IV inhibitor treatment enhanced islet neogenesis, β-cell survival, and insulin biosynthesis. In vitro studies using a β-(INS-1) cell line showed a dose-dependent prevention of STZ-induced apoptotic cell-death by both GIP and GLP-1, supporting a role for the incretins in eliciting the in vivo results. These novel findings provide evidence to support the potential utility of DP IV inhibitors in the treatment of type 1 and possibly late-stage type 2 diabetes.

AB - Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of β-cell growth, differentiation, and cell survival to well-documented, potent insulinotropic effects. Unfortunately, the therapeutic potential of these hormones is limited by their rapid enzymatic inactivation in vivo by dipeptidyl peptidase IV (DP IV). Inhibition of DP IV, so as to enhance circulating incretin levels, has proved effective in the treatment of type 2 diabetes both in humans and in animal models, stimulating improvements in glucose tolerance, insulin sensitivity, and β-cell function. We hypothesized that enhancement of the cytoprotective and β-cell regenerative effects of GIP and GLP-1 might extend the therapeutic potential of DP IV inhibitors to include type 1 diabetes. For testing this hypothesis, male Wistar rats, exposed to a single dose of streptozotocin (STZ; 50 mg/kg), were treated twice daily with the DP IV inhibitor P32/98 for 7 weeks. Relative to STZ-injected controls, P32/98-treated animals displayed increased weight gain (230%) and nutrient intake, decreased fed blood glucose (∼26 vs. ∼20 nmol/l, respectively), and a return of plasma insulin values toward normal (0.07 vs. 0.12 mmol/l, respectively). Marked improvements in oral glucose tolerance, suggesting enhanced insulin secretory capacity, were corroborated by pancreas perfusion and insulin content measurements that revealed two- to eightfold increases in both secretory function and insulin content after 7 weeks of treatment. Immunohistochemical analyses of pancreatic sections showed marked increases in the number of small islets (+35%) and total β-cells (+120%) and in the islet β-cell fraction (12% control vs. 24% treated) in the treated animals, suggesting that DP IV inhibitor treatment enhanced islet neogenesis, β-cell survival, and insulin biosynthesis. In vitro studies using a β-(INS-1) cell line showed a dose-dependent prevention of STZ-induced apoptotic cell-death by both GIP and GLP-1, supporting a role for the incretins in eliciting the in vivo results. These novel findings provide evidence to support the potential utility of DP IV inhibitors in the treatment of type 1 and possibly late-stage type 2 diabetes.

KW - DP IV, dipeptidyl peptidase IV

KW - GIP, glucose-dependent insulinotropic polypeptide

KW - GLP-1, glucagon-like peptide-1

KW - IDGTT, intraduodenal glucose tolerance test

KW - IR, immunoreactive

KW - OGTT, oral glucose tolerance test

KW - PDX-1, pancreatic-duodenum homeobox-1

UR - http://www.scopus.com/inward/record.url?scp=0037342614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037342614&partnerID=8YFLogxK

U2 - 10.2337/diabetes.52.3.741

DO - 10.2337/diabetes.52.3.741

M3 - Article

VL - 52

SP - 741

EP - 750

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -